Facebook
Twitter
Telegram
Report an ErrorSpectrum Pharmaceuticals Balance Sheet 2011-2024 | SPPI
Annual Balance Sheet Spectrum Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-10.9 M | -85.8 M | -44.5 M | -60.4 M | -157 M | -189 M | -60.9 M | -37.9 M | -30.3 M | -61.4 M | -61.4 M | -121 M |
Long Term Debt |
28.7 M | 1.45 M | - | - | - | - | 97 M | 102 M | 96.3 M | 91.5 M | 75 M | - |
Long Term Debt Current |
761 K | 1.28 M | 1.54 M | 1.68 M | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | 9.41 M | 11.1 M | 21.2 M | 26.4 M | 127 M | 132 M | 126 M | 128 M | 93 M | 14.3 M |
Total Current Liabilities |
42.7 M | 53.2 M | 53.1 M | 62 M | 86.5 M | 110 M | 65.5 M | 76.3 M | 109 M | 90 M | 128 M | 78.5 M |
Total Liabilities |
75.4 M | 64 M | 62.6 M | 73 M | 108 M | 136 M | 193 M | 208 M | 235 M | 218 M | 221 M | 92.9 M |
Deferred Revenue |
3.08 M | - | - | - | 4.85 M | 3.87 M | 3.19 M | 6.13 M | 9.96 M | 156 K | 12.3 M | 12.3 M |
Retained Earnings |
-1.12 B | -1.04 B | -885 M | -724 M | -600 M | -502 M | -403 M | -334 M | -283 M | -238 M | -179 M | -262 M |
Total Assets |
103 M | 112 M | 197 M | 263 M | 391 M | 487 M | 429 M | 421 M | 490 M | 499 M | 506 M | 281 M |
Cash and Cash Equivalents |
40.4 M | 88.5 M | 46 M | 64.4 M | 157 M | 227 M | 158 M | 140 M | 130 M | 156 M | 140 M | 121 M |
Book Value |
27.9 M | 47.6 M | 134 M | 190 M | 283 M | 351 M | 236 M | 213 M | 255 M | 282 M | 285 M | 188 M |
Total Shareholders Equity |
27.9 M | 47.6 M | 134 M | 190 M | 271 M | 351 M | 236 M | 213 M | 255 M | 282 M | 285 M | 188 M |
All numbers in USD currency
Quarterly Balance Sheet Spectrum Pharmaceuticals
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
28.8 M | 1.06 M | - | 1.14 M | 1.3 M | 1.45 M | 1.59 M | 244 K | 567 K | 883 K | 883 K | 883 K | 883 K | 2.37 M | 2.37 M | 2.37 M | 2.37 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
80.9 M | 75.4 M | - | 46 M | 44.8 M | 64 M | 68.3 M | 66.5 M | 56.6 M | 62.6 M | 62.6 M | 62.6 M | 62.6 M | 73 M | 73 M | 73 M | 73 M | 119 M | 108 M | 108 M | 108 M | 136 M | 136 M | 136 M | 136 M | 193 M | 193 M | 193 M | 193 M | 206 M | 206 M | 206 M | 206 M | 235 M | 235 M | 235 M | 235 M | 218 M | 218 M | 218 M | 218 M | 216 M | 216 M | 221 M | 221 M | 92.9 M | 92.9 M | 92.9 M | 92.9 M |
Deferred Revenue |
8.11 M | 3.08 M | - | - | - | - | - | - | - | - | - | - | - | - | 1.36 M | 7.24 M | 4.85 M | - | 4.85 M | 4.85 M | - | 3.87 M | 2.78 M | 2.55 M | 3.87 M | 3.19 M | 3.19 M | 3.19 M | 3.19 M | 6.13 M | 6.13 M | 6.13 M | 6.13 M | 9.96 M | 9.96 M | 9.96 M | 9.96 M | 156 K | 156 K | 156 K | 156 K | 12.3 M | 12.3 M | 12.3 M | 12.3 M | 12.3 M | 12.3 M | 12.3 M | 12.3 M |
Retained Earnings |
-1.12 B | -1.12 B | - | -1.09 B | -1.06 B | -1.04 B | -1 B | -971 M | -921 M | -885 M | -885 M | -885 M | -885 M | -724 M | -724 M | -724 M | -724 M | -612 M | -600 M | -600 M | -600 M | -502 M | -502 M | -502 M | -502 M | -411 M | -403 M | -403 M | -403 M | -334 M | -334 M | -334 M | -334 M | -283 M | -283 M | -283 M | -283 M | -238 M | -238 M | -238 M | -238 M | -175 M | -175 M | -179 M | -179 M | -262 M | -262 M | -262 M | -262 M |
Total Assets |
108 M | 103 M | - | 79.4 M | 100 M | 112 M | 148 M | 175 M | 179 M | 197 M | 197 M | 197 M | 197 M | 263 M | 263 M | 263 M | 263 M | 391 M | 391 M | 391 M | 391 M | 487 M | 487 M | 487 M | 487 M | 429 M | 429 M | 429 M | 429 M | 419 M | 419 M | 419 M | 419 M | 490 M | 490 M | 490 M | 490 M | 499 M | 499 M | 499 M | 499 M | 505 M | 505 M | 506 M | 506 M | 281 M | 281 M | 281 M | 281 M |
Cash and Cash Equivalents |
52.4 M | 40.4 M | - | 25.5 M | 78.7 M | 88.5 M | 107 M | 115 M | 69.5 M | 46 M | 46 M | 46 M | 46 M | 64.4 M | 64.4 M | 64.4 M | 64.4 M | 157 M | 157 M | 157 M | 157 M | 227 M | 227 M | 227 M | 227 M | 158 M | 158 M | 158 M | 158 M | 140 M | 140 M | 140 M | 140 M | 130 M | 130 M | 130 M | 130 M | 156 M | 156 M | 156 M | 156 M | 140 M | 140 M | 140 M | 140 M | 121 M | 121 M | 121 M | 121 M |
Book Value |
26.8 M | 27.9 M | - | 33.4 M | 55.3 M | 47.6 M | 79.5 M | 109 M | 122 M | 134 M | 134 M | 134 M | 134 M | 190 M | 190 M | 190 M | 190 M | 271 M | 283 M | 283 M | 283 M | 351 M | 351 M | 351 M | 351 M | 236 M | 236 M | 236 M | 236 M | 213 M | 213 M | 213 M | 213 M | 255 M | 255 M | 255 M | 255 M | 282 M | 282 M | 282 M | 282 M | 289 M | 289 M | 285 M | 285 M | 188 M | 188 M | 188 M | 188 M |
Total Shareholders Equity |
26.8 M | 27.9 M | - | 33.4 M | 55.3 M | 47.6 M | 79.5 M | 109 M | 122 M | 134 M | 134 M | 134 M | 134 M | 190 M | 190 M | 190 M | 190 M | 271 M | 283 M | 283 M | 283 M | 351 M | 351 M | 351 M | 351 M | 236 M | 236 M | 236 M | 236 M | 213 M | 213 M | 213 M | 213 M | 255 M | 255 M | 255 M | 255 M | 282 M | 282 M | 282 M | 282 M | 289 M | 289 M | 285 M | 285 M | 188 M | 188 M | 188 M | 188 M |
All numbers in USD currency